Drug Profile
Research programme: induced pluripotent stem cell therapeutics - Eisai/Keio University
Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Eisai Co Ltd; Keio University School of Medicine
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dementia; Parkinson's disease
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for research development in Parkinson's-disease in Japan
- 28 Jan 2021 No recent reports of development identified for research development in Dementia in Japan
- 19 Oct 2018 Early research in Parkinson's disease in Japan (unspecified route)